CurrentColorado Rocky Mountain Health PlansPolicy IEXD0109.08

Saphnelo (Anifrolumab‑fnia) — Coverage Criteria

Medical benefit drug policy governing coverage criteria for Saphnelo (anifrolumab-fnia) for treatment of moderate to severe systemic lupus erythematosus (SLE) under Individual Exchange plans (excludes MA, NV, NY).

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicySaphnelo (Anifrolumab‑fnia) — Coverage Criteria

Policy CodePolicy IEXD0109.08

Change TypeClinical evidence and references updatedprior version archived

Effective DateJul 1, 2025

Next Review Date

Key ActionObtain prior authorization for initial or continuation therapy with approvals limited to no more than 12 months.

SourceLink

POLICY UPDATE CHANGES

Updated Clinical Evidence and References sections to reflect the most current information; archived previous policy version IEXD0109.07.

≤12 moauthorization duration

Individual Exchangegeographic applicability

J0491, ICD M32.*codes referenced

Not for severe LN/CNSexplicit limitations

Coverage Criteria for Saphnelo (anifrolumab-fnia)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial Therapy

Covered when ALL of the following are met for initial therapy:

Initial therapy requirements: Diagnosis of moderate to severe systemic lupus erythematosus without severe active central nervous system lupus or severe active lupus nephritis; currently receiving at least one standard-of-care non-biologic treatment for active SLE (e.g., antimalarials, corticosteroids, or immunosuppressants); history of failure, contraindication, or intolerance to Benlysta IV or SQ; patient is not receiving Saphnelo in combination with a biologic agent or Benlysta; Saphnelo is dosed according to US Food and Drug Administration labeled dosing for SLE; prescribed by or in consultation with a rheumatologist; initial authorization is for no more than 12 months.

Continuation Therapy

Covered when ALL of the following are met for continuation of therapy:

Continuation therapy requirements: Patient has previously received Saphnelo injection for intravenous infusion; documentation of positive clinical response; patient is without severe active central nervous system lupus or severe active lupus nephritis; currently receiving at least one standard-of-care non-biologic treatment for active SLE (e.g., antimalarials, corticosteroids, or immunosuppressants); patient is not receiving Saphnelo in combination with a biologic agent or Benlysta; Saphnelo is dosed according to US Food and Drug Administration labeled dosing for SLE; prescribed by or in consultation with a rheumatologist; authorization is for no more than 12 months.

Coverage for Saphnelo excludes use in patients with severe active lupus nephritis or severe active central nervous system (CNS) lupus. The efficacy of Saphnelo has not been evaluated in these populations and the drug is not recommended for these indications. Providers should not submit requests for Saphnelo to treat severe active lupus nephritis or severe active CNS lupus as part of a covered indication.

Saphnelo must not be used in combination with other biologic therapies. Concurrent use with other biologics (including but not limited to belimumab) is not recommended and is an explicit coverage limitation.

Saphnelo is considered not medically necessary and unproven for the treatment of severe active lupus nephritis and severe active CNS lupus. Requests for these indications should be denied based on lack of evidence and the policy’s explicit exclusion.

Use of Saphnelo in combination with other biologic agents is also categorized as not medically necessary. Combination biologic therapy with Saphnelo has not been shown to be safe or effective and is excluded from coverage.

Procedure and Diagnosis Codes

Procedure CodesHCPCS

J0491

Injection, anifrolumab-fnia, 1 mg.

Diagnosis CodesICD-10

M32.10	Systemic lupus erythematosus, organ or system involvement unspecified.
M32.11	Endocarditis in systemic lupus erythematosus.
M32.12	Pericarditis in systemic lupus erythematosus.
M32.13	Lung involvement in systemic lupus erythematosus.
M32.14	Glomerular disease in systemic lupus erythematosus.
M32.15	Tubulo-interstitial nephropathy in systemic lupus erythematosus.
M32.19	Other organ or system involvement in systemic lupus erythematosus.
M32.8	Other forms of systemic lupus erythematosus.
M32.9	Systemic lupus erythematosus, unspecified.

inv-07: Glucocorticoid taper requirement (trials)

Trial taper requirementFor patients with baseline glucocorticoid ≥10 mg/day, an attempted taper to ≤7.5 mg/day prednisone (or equivalent) was required from Weeks 8–40 and defined as sustained when maintained through Week 52.

Baseline thresholdApplies only when baseline oral glucocorticoid dose is ≥10 mg/day.

Taper windowTaper attempt window specified as Weeks 8 through 40 of the 52‑week trials.

Sustained reduction definitionSustained reduction is considered when the reduced dose (≤7.5 mg/day) is maintained through Week 52.

Relevance to outcomesPooled TULIP analyses showed more patients who achieved sustained glucocorticoid reductions from ≥10 mg/day remained flare‑free with anifrolumab versus placebo.

Prior Authorization, Documentation, and Prescriber Requirements

Prior Authorization

Prior Authorization and Coding

Prior authorization is required for both initiation and continuation of Saphnelo (anifrolumab-fnia). Approvals are limited to a maximum of 12 months per authorization. Use HCPCS J0491 (Injection, anifrolumab-fnia, 1 mg) when billing.

Prior authorization required for initial and continuation therapy
Approvals limited to up to 12 months per authorization
Bill using HCPCS J0491 (anifrolumab-fnia, 1 mg)

Denial Risk

Triggers for Denial

Saphnelo will be denied when any of the following apply: severe active lupus nephritis, severe active central nervous system (CNS) lupus, or when Saphnelo is prescribed in combination with another biologic agent (including Benlysta).

Use in patients with severe active lupus nephritis — denial trigger
Use in patients with severe active CNS lupus — denial trigger
Concurrent use with other biologic agents (including Benlysta) — denial trigger

Step Therapy

Step Therapy / Prior Biologic Requirement

Prior to approval, the member must currently be receiving at least one standard-of-care non-biologic therapy for active SLE (e.g., antimalarials, corticosteroids, or non-biologic immunosuppressants). Additionally, there must be history of failure, contraindication, or intolerance to Benlysta (IV or SQ) before initiating Saphnelo.

Patient must be currently receiving ≥1 standard-of-care non-biologic treatment for active SLE (examples: antimalarials, corticosteroids, non-biologic immunosuppressants)
Documented history of failure, contraindication, or intolerance to Benlysta (IV or SQ) prior to initiation

Key Definitions and Trial Endpoints

inv-13: Definitions of SRI and BICLA

SRI (SLE Responder Index)A composite trial endpoint used to assess clinical response (SRI[4] reported at week 24 and week 52 in pivotal studies).

BICLA (BILAG‑based Composite Lupus Assessment)A composite measure used as a trial endpoint to assess clinical response; reported alongside SRI in phase II/III trials.

Use in trialsBoth SRI and BICLA were prespecified efficacy end points in the anifrolumab phase II and TULIP phase III programs (assessed at weeks 24 and 52).

Clinical interpretationImprovements in SRI and BICLA with anifrolumab contributed to conclusions that treatment reduced disease activity versus placebo in moderate‑to‑severe SLE.